Skip to main content

Table 2 Details of HER2amp CTC detection and characteristics (*) HER2/CEP17 number and ratio in the 17 detected HER2amp CTC were as follows: 3/1/3.0 for each of the 17 CTC.

From: Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Patient

Step

No. of CTC detected

(/7.5 ml)

No. of CTC with FISH

No. of HER2amp CTC

HER2 and CEP17 for each HER2amp CTC

N CEP17

N HER2

HER2/CEP17 ratio

Patients screened with HER2amp CTC, with no further sample (not treated or not assessed)

03-020-1

Screening

9

2

1

1

3

3.0

03-030-1

Screening

247

61

1

1

3

3.0

03-031-1

Screening

69

28

1

2

6

3.0

03-039-1

Screening

111

19

1

1

7

7.0

04-003-1

Screening

30

8

1

2

6

3.0

10-004-1

Screening

39

2

1

2

5

2.5

03-037-2

Screening

308

51

5

2

6

3.0

2

6

3.0

2

5

2.5

2

5

2.5

2

5

2.5

10-005-2

Screening

475

92

6

1

10

10.0

1

10

10.0

1

8

8.0

1

3

3.0

2

5

2.5

2

5

2.5

Patients screened with HER2amp CTC with sample during therapy

01-017-1

Screening

22

7

2

1

3

3.0

1

3

3.0

Cycle #2

9

5

0

   

Progression

22

9

0

   

05-005-1

Screening

32

7

2

1

3

3.0

1

3

3.0

Cycle #2

10

6

0

   

05-006-2

Screening

17

10

6

1

3

3.0

1

3

3.0

1

3

3.0

1

3

3.0

1

3

3.0

1

3

3.0

Cycle #2

57

31

17

(*) see caption

07-010-1

Screening

397

167

2

1

5

5.0

2

8

4.0

Cycle #2

445

216

3

2

10

5.0

3

10

3.3

1

3

3.0

08-001-1

Screening

355

171

1

1

3

3.0

Cycle #2

136

95

3

1

6

6.0

2

6

3.0

1

3

3.0

Progression

665

484

4

1

3

3.0

1

3

3.0

1

3

3.0

2

5

2.5

08-002-1

Screening

275

107

2

1

4

4.0

2

5

2.5

Cycle #2

242

70

5

1

4

4.0

1

3

3.0

1

3

3.0

1

3

3.0

1

3

3.0

1

3

3.0